Generate Biomedicines’ $400M IPO Puts AI Drug Discovery Back in Focus

oncodaily - Generate Biomedicines priced its U.S. initial public offering on February 26, 2026, selling 25 million shares at $16 each for gross proceeds of $400 million, with trading expected on the Nasdaq under […]

AI Summary: Generate Biomedicines priced a U.S. IPO at $16 per share, selling 25 million shares and raising about $400 million to advance AI-designed drugs — notably a less-frequent injection candidate for severe asthma. The offering renews investor appetite for AI-driven biotech and funds pivotal clinical work, while whispering about a lofty post-listing valuation.

#healthcare #pharmaceuticals #biotech #drugdevelopment #digitalhealth #healthcarefinance

China obesity biotech QL Biopharm gets $72M, including support from OrbiMed

4 months / endpoints / Kyle LaHucik

Minding the gap – what does China’s biotech boom mean for the UK?

4 months / cancerresearchuk / Tim Bodicoat

Generate Biomedicines’ $400M IPO Puts AI Drug Discovery Back in Focus

4 months / oncodaily

Generate Biomedicines’ IPO Brings In $400M for Pivotal Tests of Severe Asthma Drug

4 months / medcitynews / Frank Vinluan

Generate:Biomedicines raises $400M IPO, CEO talks about AI's future in drug design

4 months / endpoints / Andrew Dunn

AbbVie budgets $380M for obesity and neuroscience API facilities in Chicago

4 months / endpoints / Anna Brown

Generate Biomedicines’ $400M IPO Puts AI Drug Discovery Back in Focus

Related Stories